Biocon Ltd
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Biocon Ltd's management has articulated a positive outlook, particularly for its biosimilars and generics segments, as the company transitions from an investment phase to a focus on operational execution and margin expansion. The integration of the Viatris biosimilars business is expected to enhance scale and competitiveness, with a robust pipeline of new product launches anticipated to drive revenue growth. Vista's forecast reflects an expected acceleration in revenue growth, projecting a 16% CAGR through FY28, supported by the successful commercialization of new biosimilars and improved capacity utilization. However, challenges remain, particularly in the Syngene research services segment, which is undergoing a transition aimed at operational efficiency. The broader industry context is favorable, with Indian CDMOs gaining traction amid global supply chain diversification, although competitive pricing pressures persist. Over the next 12-24 months, key opportunities include the launch of high-value GLP-1 therapies and the potential for margin improvement through operational leverage. Conversely, watchpoints include the gestation period for Syngene's recovery and ongoing pricing pressures in mature markets, which could impact overall profitability
Why We Like This Stock
- Successful integration of the Viatris biosimilars business enhances scale and market competitiveness
- A robust pipeline of new biosimilars and GLP-1 therapies is expected to drive significant revenue growth
- Management's focus on operational efficiency and margin expansion supports a positive long-term outlook
Things To Watch Out For
- The Syngene segment is undergoing a transition, which may delay revenue recovery and operational stability
- Pricing pressures in mature markets could impact margins and profitability
- Geopolitical uncertainties and supply chain challenges may pose risks to sustained growth
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 14,756 | 15,262 | 16,297 | 17,772 | 19,948 |
| Profit Before Tax (Cr.) | 1,469 | 1,840 | 851 | -416 | 295 |
| PBT Margin | 10.0% | 12.1% | 522.2% | -2.3% | 1.5% |
| Net Profit (Cr.) | 1,398 | 1,549 | 334 | -312 | 210 |
| Earnings Per Share | 6.9 | 7.0 | 2.2 | -1.8 | 1.3 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Bernstein | ▼ Underperform | 326 | 07-Aug-2026 |
| Citigroup | ▼ Sell | 360 | 07-Aug-2026 |
| DAM Capital | ▼ Sell | 495 | 14-Jul-2026 |
| HSBC | ▲ Buy | 490 | 07-Aug-2026 |
| Jeffries | ► Hold | 410 | 07-Aug-2026 |
| Motilal Oswal | ▲ Buy | 520 | 07-Aug-2026 |
Company Overview
Show Company Profile
Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services, and other research and development in the fields of pharmaceuticals, drug discovery, biotechnology pharmaceuticals, and medicinal sciences, etc.; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.